Colony Group’s Sarepta Therapeutics SRPT Stock Holding History

Colony Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$203K	Buy	+1,672	New	+$189K	﹤0.01%	729
2023 Q2	–	Sell	-1,674	Closed	-$231K	–	799
2023 Q1	$231K	Buy	1,674 +8	+0.5%	+$1.04K	﹤0.01%	715
2022 Q4	$216K	Buy	+1,666	New	+$193K	﹤0.01%	781
2021 Q1	–	Sell	-1,676	Closed	-$286K	–	785
2020 Q4	$286K	Sell	1,676 -40	-2%	-$5.93K	0.01%	627
2020 Q3	$241K	Hold	1,716	–	–	0.01%	643
2020 Q2	$275K	Buy	+1,716	New	+$234K	0.01%	572
2020 Q1	–	Sell	-1,716	Closed	-$221K	–	766
2019 Q4	$221K	Buy	+1,716	New	+$173K	0.01%	699
2019 Q3	–	Sell	-1,716	Closed	-$261K	–	724
2019 Q2	$261K	Sell	1,716 -30	-2%	-$3.65K	0.01%	643
2019 Q1	$208K	Buy	+1,746	New	+$224K	0.01%	598
2018 Q4	–	Sell	-1,746	Closed	-$282K	–	537
2018 Q3	$282K	Hold	1,746	–	–	0.01%	425
2018 Q2	$231K	Buy	+1,746	New	+$165K	0.01%	452

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Colony Group's SRPT Position: Q3 2023 in Review

Colony Group opened a new position in Sarepta Therapeutics (SRPT) in Q3 2023: 1,672 shares worth $203K. The stake represents ﹤0.01% of the portfolio and ranks #729 among its holdings. This is a return to the name: Colony Group previously reported a position in SRPT as recently as Q1 2023.

Colony Group first reported a position in SRPT in Q2 2018 and has held it in 11 quarters since. The position peaked at $286K in Q4 2020. 395 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

Colony Group held 1,672 shares of Sarepta Therapeutics worth $203K as of Q3 2023.
Sarepta Therapeutics was a new Colony Group position in Q3 2023.
Sarepta Therapeutics made up ﹤0.01% of Colony Group's portfolio in Q3 2023, its #729 holding.
Colony Group first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 11 quarters since.
Colony Group's Sarepta Therapeutics position peaked at $286K in Q4 2020.
395 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.